I did pick NKTR last year and won the contest. I just did not want to win 2 years in a row. Not healthy for my ego. hehehe
VX-765 has already been shown to be safe so it seems to me VRTX could run a combined phase1 phase 2 trial on its own rather than through a partnership and if the results are very good, develop the drug in house rather than through a partnership. Even if VRTX has to do dilution to raise fund for a phase 3 I think it is worth it. Again that is assuming the phase 2 results show good efficacy.
The problem is that I do not believe you can enforce a BVI rule or court ruling in China to distribute the company's assets, if any.
The only way we can get any thing is if the IPO money is out of China and the court rules that it must be distributed to all who lost money on the stock.
"The [global opportunities] I quoted was originally from the CFO Ian Smith two CC ago"
I do not recall that . Good info.
At least someone at vrtx mgt is sane. It sounds like what Stuart was talking about was his own view and not the whole of VRTX mgt.
"CCO is placing his bar above Sofosbuvir. VX-135 does not have to be superior to Sof in every respect."
I totally agree with you and I was annoyed when I read the CCO's comment in the transcript of the conference. The question that remains is that when he is saying it is "crystal," have the rest of the management agreed with the 90% bar he talked about or did he just come up with that on his own without doing much thinking.
My fear is that the management may have decided that if a drug does not at least match the efficacy of competing drugs, that it is beneath them to mess with it. Of course I hope I am wrong.